Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy

International IgA Nephropathy Network, Mark Canney, Sean J. Barbour*, Yuyan Zheng, Rosanna Coppo, Hong Zhang, Zhi Hong Liu, Keiichi Matsuzaki, Yusuke Suzuki, Ritsuko Katafuchi, Heather N. Reich, Daniel Cattran, M. L. Russo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

35 Citations (Scopus)

Abstract

BACKGROUND: On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria needs to be maintained to mitigate the long-term risk of disease progression is unknown.

METHODS: In this retrospective multiethnic cohort of adult patients with IgA nephropathy, we defined proteinuria remission as a ≥25% reduction in proteinuria from the peak value after biopsy, and an absolute reduction in proteinuria to <1 g/d. The exposure of interest was the total duration of first remission, treated as a time-varying covariate using longitudinal proteinuria measurements. We used time-dependent Cox proportional hazards regression models to quantify the association between the duration of remission and the primary outcome (ESKD or a 50% reduction in eGFR).

RESULTS: During a median follow-up of 3.9 years, 274 of 1864 patients (14.7%) experienced the primary outcome. The relationship between duration of proteinuria remission and outcome was nonlinear. Each 3 months in sustained remission up to approximately 4 years was associated with an additional 9% reduction in the risk of disease progression (hazard ratio [HR], 0.91; 95% confidence interval [95% CI], 0.89 to 0.93). Thereafter, each additional 3 months in remission was associated with a smaller, nonsignificant risk reduction (HR, 0.99; 95% CI, 0.96 to 1.03). These findings were robust to multivariable adjustment and consistent across clinical and histologic subgroups.

CONCLUSIONS: Our findings support the use of proteinuria as a surrogate outcome in IgA nephropathy, but additionally demonstrate the value of quantifying the duration of proteinuria remission when estimating the risk of hard clinical endpoints.

Original languageEnglish
Pages (from-to)436-447
Number of pages12
JournalJournal of the American Society of Nephrology
Volume32
Issue number2
DOIs
Publication statusPublished - Feb 2021

Bibliographical note

Copyright © 2021 by the American Society of Nephrology.

Fingerprint

Dive into the research topics of 'Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy'. Together they form a unique fingerprint.

Cite this